Emmessar Biotech sets 34th AGM for September 29 via video conferencing

1 min read | Published on 27 Aug 2026, 02:58 PM |Updated on 27 Aug 2026, 02:58 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Emmessar Biotech schedules its 34th AGM for September 29, 2026
The meeting will be held via video conferencing starting at 10:30 am
Notices and annual reports for FY26 are sent electronically only
Shareholders must register email IDs with RTA or DP to access documents

*this image is generated using AI for illustrative purposes only.

Emmessar Biotech & Nutrition Ltd has scheduled its 34th Annual General Meeting for September 29, 2026. The event will be conducted through video conferencing and other audio-visual means.

The meeting is set to begin at 10:30 am on Tuesday. The company issued the notice in compliance with Ministry of Corporate Affairs circulars and SEBI listing regulations. These guidelines permit holding meetings remotely and distributing documents electronically.

Shareholder Instructions

Shareholders will receive the AGM notice and annual report for FY26 only through electronic mode. This applies exclusively to members who have registered their email addresses with the Registrar and Share Transfer Agent or Depository Participant.

Investors without registered email IDs must update their details to participate. They can do so by logging into the MUFG Intime India Private Limited website under Investor Services. Alternatively, demat account holders should contact their Depository Participant directly.

Voting and Accessibility

E-voting login details will be sent to registered email addresses. The AGM notice will also be available on the company website and the stock exchange portal. Members can attend and vote using the video conferencing facility provided.

What the Numbers Show

The reliance on electronic communication highlights a shift toward digital shareholder engagement. By restricting physical copies to those without registered emails, the company streamlines its distribution process while maintaining regulatory compliance.

Historical Stock Returns for Emmessar Biotech

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.72%	-2.96%	-3.76%	-6.06%	-13.37%	0.0%

How might Emmessar's strict digital-only AGM policy impact participation rates among older or less tech-savvy shareholders?

What are the potential cybersecurity risks associated with holding the entire AGM and voting process remotely, and how is the company mitigating them?

Could this shift to fully electronic communication signal a broader trend in Indian biotech firms reducing operational costs through digital transformation?

Emmessar Biotech

View Company Insights

View All News

Emmessar Biotech & Nutrition net profit rises 23% in Q1FY27

2 min read | Published on 07 Aug 2026, 02:43 PM |Updated on 08 Aug 2026, 02:34 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Emmessar Biotech & Nutrition Ltd reported a 23% YoY rise in Q1FY27 net profit to ₹13.15 lakh, driven by stable rental income from leasehold land and effective cost management. Total income reached ₹59.85 lakh.

*this image is generated using AI for illustrative purposes only.

Emmessar Biotech & Nutrition Limited reported a net profit of ₹13.15 lakh for the quarter ended June 30, 2026, marking a 23% year-on-year increase from ₹10.70 lakh in the corresponding period of FY26. The growth was primarily driven by stable rental income from its leasehold land segment, which contributed ₹41.33 lakh to total income, alongside effective cost management that reduced total expenses to ₹43.55 lakh from ₹45.24 lakh in the previous quarter.

The Board of Directors approved the unaudited financial results on August 07, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results underwent a limited review by statutory auditors M/s. V. Nagarajan & Co., Chartered Accountants, who issued their report on the same date. The financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and other generally accepted accounting principles in India.

Financial Performance Breakdown

Revenue from operations stood at ₹5.93 lakh, down from ₹9.28 lakh in the preceding quarter but aligned with the ₹9.28 lakh recorded in Q1FY26. This decline was offset by significant other income, which totaled ₹53.92 lakh compared to ₹47.34 lakh in the previous quarter. The healthcare segment generated ₹5.93 lakh in revenue, while the rent on leasehold land segment contributed ₹41.33 lakh. The 'Others' category added ₹12.59 lakh to the top line.

Metric	Q1FY27 (₹ Lakh)	Q4FY26 (₹ Lakh)	Q1FY26 (₹ Lakh)
Revenue from Operations	5.93	9.28	9.28
Other Income	53.92	47.34	53.42
Total Income	59.85	56.62	62.70
Total Expenses	43.55	48.67	39.57
Profit Before Tax	16.30	7.96	23.13
Net Profit After Tax	13.15	3.42	10.70

Employee benefit expenses were the largest cost component at ₹30.32 lakh, followed by other expenditure at ₹9.06 lakh. Cost of material consumed was minimal at ₹2.36 lakh. Finance costs remained negligible at ₹0.07 lakh. The company recorded no exceptional items during the quarter.

What the Numbers Show

The primary driver of profitability remains the non-operational income stream, particularly rent from leasehold land, which constitutes the bulk of both revenue and profit. While core healthcare operations generated modest revenue of ₹5.93 lakh, the segment’s result was ₹4.11 lakh, indicating healthy margins despite lower volume compared to the prior year. The divergence between operating revenue and total income highlights the company’s reliance on asset leasing for cash flow stability. Earnings per share (basic) stood at ₹0.26, up from ₹0.01 in the previous quarter and ₹0.34 in Q1FY26.

Corporate Governance and AGM Details

The company announced that its 34th Annual General Meeting will be held on September 29, 2025, via video conferencing. Shareholders holding shares as of September 22, 2026, are eligible to vote electronically. The remote e-voting period will commence on September 26, 2026, and conclude on September 28, 2026. The meeting will be conducted in compliance with MCA General Circulars and SEBI circulars regarding virtual meetings. No investor complaints were received during the quarter ended June 30, 2026.

Historical Stock Returns for Emmessar Biotech

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.72%	-2.96%	-3.76%	-6.06%	-13.37%	0.0%

Will Emmessar Biotech consider divesting its leasehold land assets to reinvest capital into its core healthcare operations, given the disparity in revenue contribution?

How does the company plan to scale its healthcare segment revenue beyond the current ₹5.93 lakh run rate to reduce dependency on non-operational income?

What is the long-term strategy for maintaining rental income stability amidst potential regulatory changes or market fluctuations in real estate leasing?

Emmessar Biotech

View Company Insights

View All News